Clinical trials: Lower Urinary Tract Symptoms
Non-muscle Invasive Bladder Cancer (NMIBC)
Hyaluronic Acid Sodium Salt and Hydeal-D in the Management of LUTS After TURBT for NMIBC.
This will be an open-label, prospective, single-centre, randomised, controlled, parallel-group medical device investigation. The investigational plan will include four visits in total at the investigational site.
- Trial name
- NCT06069453
- Testing
- Hyaluronic Acid (HA) sodium salt and Hydeal-D
- Where
- Italy
- Volunteers
- 54 people
- Sponsor
- Fidia Farmaceutici s.p.a.
Overactive Bladder, Urinary Incontinence
A Research Study for Patients With Overactive Bladder
The purpose of this study is to investigate whether injections of botulinum toxin Type A into the bladder are safe and effective in treating overactive bladder.
- Trial name
- NCT00168454
- Testing
- botulinum toxin Type A
- Where
- 6 sites in United States, Belgium and 4 more
- Volunteers
- 313 people
- Sponsor
- Allergan
Benign Prostatic Hyperplasia
Interest of a Systematic Assessment of the Treatment of LUTS in the Management of BPH
The high level of unsatisfactory outcome observed in patients treated for LUTS associated with BPH with respect to the different existing therapeutic options strongly emphasizes the need for treatment optimisation in daily…
- Trial name
- UROEVAL (NCT03179670)
- Where
- France
- Volunteers
- 625 people
- Sponsor
- RECORDATI GROUP
Lower Urinary Tract Symptoms (LUTS), Overactive Bladder (OAB)
Vesitirim™ in Men Postmarketing Observational Study
This is an observational study which will look at the improvement in Lower Urinary Tract Symptoms (LUTS) in Irish men being treated with Vesitirim™ (solifenacin).
- Trial name
- VIM (NCT01639794)
- Testing
- Vesitirim™ (Solifenacin)
- Where
- 5 sites in Ireland
- Volunteers
- 12 people
- Sponsor
- Astellas Pharma Europe Ltd.
Urination Disorders
An Effectiveness and Safety Study Comparing Oxybutynin Chloride Plus FLOMAX (Tamsulosin HCl) and Placebo Plus FLOMAX (Tamsulosin HCl) for the Treatment of Lower Urinary Tract Symptoms.
The purpose of this study is to evaluate the safety and effectiveness of oxybutynin extended release tablets 10 mg plus tamsulosin HCl 0.4 mg in the treatment of lower urinary tract symptoms as measured by change of the total…
- Trial name
- NCT00338624
- Testing
- oxybutynin chloride extended release
- Volunteers
- 420 people
- Sponsor
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Urinary Incontinence, Over Active Bladder
Sacral Neuromodulation With InterStim® Therapy for Intractable Urinary Voiding Dysfunctions (SOUNDS): an Observational Study
The purpose of this study is to document the safety, the effectiveness, the continued performance at mid and long term, the morbidity and the percent of surgical revisions of the Interstim® therapy for up to 5 years in a…
- Conditions
- Urinary Incontinence, Over Active Bladder, Urinary Retention
- Trial name
- SOUNDS (NCT02186041)
- Testing
- Sacral Nerve Modulation
- Where
- 24 sites in France
- Volunteers
- 320 people
- Sponsor
- MedtronicNeuro
Overactive Bladder (OAB)
Drug Use Investigation for Toviaz
The purpose of this study is to collect effectiveness and safety information of fesoterodine related to their appropriate use in daily practice.
- Trial name
- NCT01936870
- Testing
- Fesoterodine (Toviaz)
- Volunteers
- 2,521 people
- Sponsor
- Pfizer
Nocturia
Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of Fedovapagon
The purpose of this study is to investigate the potential for co-administration of strong inhibitors or inducers of CYP3A4 to alter the pharmacokinetics of fedovapagon.
- Trial name
- NCT02440841
- Testing
- fedovapagon, Itraconazole, rifampicin
- Where
- Germany
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Vantia Ltd
Overactive Bladder
Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder
To evaluate the efficacy and safety after 12 weeks oral administration of Imidafenacin 0.1mg b.i.d versus Fesoterodine 4mg once daily for the urge incontinence and/or increased urinary frequency associated with urgency as may…
- Trial name
- NCT01578304
- Testing
- Imidafenacin, Fesoterodine
- Where
- South Korea
- Volunteers
- 207 people
- Sponsor
- LG Life Sciences
Overactive Bladder, Cardiovascular Disease
Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease
This purpose of this study is to investigate the effects of mirabegron on the cardiovascular system in patients with overactive bladder with current or a history of cardiovascular disease.
- Trial name
- NCT02570035
- Testing
- Mirabegron
- Where
- 28 sites in Japan
- Volunteers
- 316 people
- Sponsor
- Astellas Pharma Inc
Urinary Bladder, Overactive
Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan).
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors…
- Trial name
- NCT00795509
- Testing
- Tolterodine tartrate
- Volunteers
- 374 people
- Sponsor
- Pfizer
Overactive Bladder
Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2")
The study will investigate the safety and efficacy of UroGen's TC-3 Gel for sustained release of Botulinum Toxin A (BTX) in urinary bladder in patients with idiopathic overactive bladder.
- Trial name
- INTIMO2 (NCT02674269)
- Testing
- 300 IU of BotuGelTM (60ml), 400 IU of BotuGelTM (60ml), TC-3 Gel
- Where
- 2 sites in Israel
- Sponsor
- UroGen Pharma Ltd.
Incontinence, Urinary and Urinary Bladder, Overactive, Overactive Bladder
Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients
This is a two-part study in which Part A will assess the effects of GW679769 after 1 dose on the function of the nerves that supply the bladder. The technique for measuring the nerves function is called Neurometry.
- Trial name
- NCT00332319
- Testing
- GW679769
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Urinary Incontinence, Overactive Bladder
A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients
This is a safety and efficacy study of BOTOX® (Botulinum Toxin Type A) in the Treatment of Adult Korean Patients with Urinary Incontinence due to Neurogenic Detrusor Overactivity or Overactive Bladder.
- Trial name
- NCT02601287
- Testing
- Botulinum Toxin Type A
- Where
- 5 sites in South Korea
- Volunteers
- 168 people
- Sponsor
- Allergan
Overactive Bladder
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
To evaluate the NURO system for the treatment of OAB in drug naïve patients.
- Trial name
- RESET (NCT02857816)
- Testing
- NURO System PTNM Therapy
- Where
- 11 sites in United States
- Volunteers
- 154 people
- Sponsor
- MedtronicNeuro
Stress Urinary Incontinence
GTx-024 as a Treatment for Stress Urinary Incontinence in Women
The purpose of this study is to determine whether GTx-024 is safe and effective in the treatment of stress urinary incontinence in postmenopausal women.
- Trial name
- NCT02658448
- Testing
- GTx-024
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- GTx
Overactive Bladder
Dose-Escalating Study of Propiverine Hydrochloride in Children Suffering From Overactive Bladder
The open-label dose-escalating two-centre study was designed to assess the pharmacokinetics as well as safety, tolerability and efficacy parameters of propiverine in patients 5-10 years of age suffering from…
- Trial name
- NCT00795925
- Testing
- propiverine hydrochloride
- Volunteers
- 30 people
- Sponsor
- APOGEPHA Arzneimittel GmbH
Spinal Cord Injury (SCI), Chronic Urinary Retention
Tissue Bonding Cystostomy(TBC)
Spinal Cord Injured [SCI] patients typically cannot "pee". Injury to the spinal cord disrupts the in-coming and out-going brain signals that coordinate bladder sensation and the emptying of bladder.
- Conditions
- Spinal Cord Injury (SCI), Chronic Urinary Retention, Urinary Incontinence
- Trial name
- TBC (NCT01771159)
- Testing
- TBC
- Volunteers
- 10 people
- Sponsor
- Uro-Research, LLC
Stress Urinary Incontinence
Lyrette: Renewing Continence Objective and Subjective Efficacy Study
The purpose of this study is to demonstrate the treatment efficacy of the Lyrette® System in women most likely to be treated in an office setting for the condition of stress urinary incontinence, secondary to urethral…
- Trial name
- ROSE (NCT01455779)
- Testing
- Lyrette
- Where
- 6 sites in United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Verathon
Urinary Incontinence
A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder
The main aim of the study is to investigate whether taking Tolterodine for overactive bladder symptoms can reduce the thickness of the bladder wall, as measured by intra-vaginal ultrasound.
- Trial name
- NCT00137397
- Testing
- Tolterodine ER
- Where
- 11 sites in United Kingdom
- Volunteers
- 80 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.